CA-MRSA Infection in China: Epidemiology, Molecular Characteristics, Treatment, and Outcome
Community-associated Staphylococcus Aureus Infections in China: Epidemiology, Molecular Characteristics, Treatment, and Outcome
1 other identifier
observational
5,400
1 country
1
Brief Summary
Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), strains of MRSA that are able to infect otherwise healthy people outside of hospital settings, emerged in the late 1990s and have recently arisen in many countries around the globe. CA-MRSA strains are usually distinguished from their HA-MRSA counterparts by the following characteristics: Firstly, CA-MRSA strains are usually susceptible to non-lactam antibiotics. Secondly, CA-MRSA harbors type IV and V SCCmec elements, which are shorter than the traditional type I, II, and III SCCmec elements found in HA-MRSA strains. Thirdly, certain successful clones are associated with outbreaks of CA-MRSA infections reported in specific geographical locations. For example, ST1 and ST8 isolates are mostly reported in the USA and Canada, ST80 isolates are commonly found in Europe, and ST59 isolates are encountered in the Asia-Pacific region. Notably, all these characteristics have substantial limitations for discriminating CA-MRSA isolates due to their complex backgrounds. Although there were more and more studies of CA-MRSA in European countries and the US, few national epidemiological data were available about China. In this study, we investigated the epidemiological, clinical and molecular characteristics of CA-MRSA isolates recovered in Chinese hospitals, in order to understand the changing epidemiology of MRSA in China.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2016
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 15, 2016
CompletedFirst Submitted
Initial submission to the registry
February 22, 2017
CompletedFirst Posted
Study publicly available on registry
February 27, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2018
CompletedFebruary 27, 2017
February 1, 2017
1 year
February 22, 2017
February 22, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The incidence of CA-MRSA infections in China
Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection rates in patients with S. aureus infections in Chinese hospitals
During the study period (Two years)
Secondary Outcomes (1)
Clonal Distribution of CA-MRSA in China
During the study period (Two years)
Study Arms (3)
CA-MRSA infection
None intervention
HA-MRSA infection
None intervention
CA-MSSA infection
None intervention
Interventions
It is observational study, no interventios to any of the three study arms
Eligibility Criteria
All child and adult patients with Staphylococcus aureus visited any of the 60 particitant hospitals during the study period were included.
You may qualify if:
- Patients (Child, Adult) with infections caused by S. aureus from the sites as follows: blood stream, skin or soft tissue, cerebrospinal fluid, bone and joint, genitourinary tract, infection of indwelling intravascular device, surgical wound, respiratory tract (organism grown from sputum and infiltrate on chest X-ray), peritoneal fluid or other otherwise sterile body fluids.
You may not qualify if:
- Patients with S. aureus from anterior nares or throat swabs cultures for colonization screening purpose.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Sir Run Run Shaw Hospital
Hangzhou, Zhejiang, 310016, China
Biospecimen
bacterial isolates
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Yun-song Yu, MD
Sir Run Run Shaw Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Department of Infectious Diseases
Study Record Dates
First Submitted
February 22, 2017
First Posted
February 27, 2017
Study Start
December 15, 2016
Primary Completion
December 31, 2017
Study Completion
June 30, 2018
Last Updated
February 27, 2017
Record last verified: 2017-02